Lipid Profiling Can Predict Future Risk for Type 2 Diabetes, CVD
In the highest-risk groups for T2D and CVD, significantly altered lipidome compositions affected 167 and 157 lipid species, respectively
Diabetes
Six Percent With Prediabetes Develop Diabetes Within 1 Year
Diabetes development more likely for those with higher glycemic level, BMI ≥30 kg/m2 and among Black versus White individuals
Management of Drug-Induced Diabetes Discussed in Review
The study authors focused on 4 pharmacologic classes: glucocorticoids, antiretroviral therapies, newer atypical antipsychotics, and immune checkpoint inhibitors.
E-Cigarette Use Linked to Increased Odds of Prediabetes
Increased odds ratios for prediabetes seen for current and former e-cigarette users compared with never users
February 2022 Recap: Drug Pipeline Updates
A review of regulatory and drug development status updates.
Provention Bio Resubmits BLA for Teplizumab to Delay Type 1 Diabetes
Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
SGLT2is, SGLT2i/GLP-1RA May Prevent CV Events in T2DM
Current use of SGLT2is, GLP-1RAs, and their combination associated with significantly reduced risk of heart failure events
NOACs May Be Better Choice for Patients With A-Fib and DM
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Adding Tirzepatide to Insulin Glargine Ups Glycemic Control in T2DM
For adults with type 2 diabetes and inadequate glycemic control, glycemic control improved with addition of tirzepatide versus placebo
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
